Clyde has worked closely with the majority of large pharmaceutical companies, CiPA, HESI and the FDA to validate the CellOPTIQ® platform.
A broad range of reference and therapeutic compounds have been tested to demonstrate that CellOPTIQ®:
- Is predictive of the clinical setting (correlates well with patient ECG)
- Is predictive of in vivo models especially compounds with multi ion channel effects or effects on contractility
- Offers significant advantages over other platforms
- Provides very low false negative liability
Validation Experiments with Pharmaceutical Companies’ Compounds Demonstrate the Power of CellOPTIQ®
Comparison of CellOPTIQ with Rabbit Wedge and Other Modalities Using 19 Reference Compounds
CellOPTIQ® outclasses many of the comparable platforms, especially in the identification of known reference compounds. CellOPTIQ® was the only platform without a false negative liability.
CellOPTIQ® Generates Data Which is Predictive of the Clinical Setting
Positive correlation observed between results of Axiogenesis hiPSC-CMs tested in vitro on CellOPTIQ® system and human EP treated with same range of Quinidine concentrations.
“I would do a voltage sensitive dye study on the myocyte” – Major Pharma, Global Head of Safety
“A reasonable approach” – FDA Physician